Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome

Alogliptin, a dipeptidyl peptidase‐4 inhibitor, is approved for the treatment of patients with type 2 diabetes (T2DM). EXAMINE was a randomized controlled clinical trial designed to demonstrate the cardiovascular (CV) safety of alogliptin. In the trial, 5380 patients with established T2DM who had a...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cardiol
Hlavní autoři: Cavender, Matthew A., White, William B., Liu, Yuyin, Massaro, Joseph M., Bergenstal, Richard M., Mehta, Cyrus R., Zannad, Faiez, Heller, Simon, Cushman, William C., Cannon, Christopher P.
Médium: Artigo
Jazyk:Inglês
Vydáno: Wiley Periodicals, Inc. 2018
Témata:
Clinical Trial Updates
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6489788/
https://ncbi.nlm.nih.gov/pubmed/29652078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22960
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky